Chromosomes, hypoxia, angiogenesis, and trial design: A brief history of renal cancer drug development

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1630-1633

  Stadler, Walter ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CYTOSTATIC AGENT; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; VHL PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CHROMOSOME 3P; CLINICAL TRIAL; GENE; HISTORY; HUMAN; HYPOXIA; KIDNEY CANCER; PRIORITY JOURNAL; BIOLOGICAL MODEL; CELL HYPOXIA; DRUG DESIGN; DRUG SCREENING; GENETICS; HUMAN CHROMOSOME; KIDNEY TUMOR; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CHROMOSOMES, HUMAN; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; RESEARCH DESIGN; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 34250206652     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2721     Document Type: Article

References (27)

1. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
2. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene [see comments]. Science 1993;260:1317-20.
3. Banks RE, Tirukonda P, Taylor C, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006;66:2000-11.
4. Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-8.
5. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-3.
6. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993;90:4304-8.
7. Semenza GL. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exp Physiol 2006;91:803-6.
8. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-61.
9. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271 -5.
10. 2 sensing. Science 2001;292:464-8.
11. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
12. Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290-5S.
13. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006;580:2879-87.
14. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006;81:1241-57.
15. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comments]. J Natl Cancer Inst 2000;92:205-16.
17. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002;20:4478-84.
18. Kuenen BC, Giaccone G, Ruijter R, et al. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res 2005;11:6240-6.
19. Kuenen BC, Tabernero J, Baselga J, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003;9:1648-55.
20. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
21. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
22. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol 2006;24:LBA3.
23. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
24. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505- 12.
25. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 2005;24:LBA4510.
26. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
27. Hudes G, Carducci M, Tomczak P, et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon-α or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma [abstract]. J Clin Oncol 2006;24:LBA4.